Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04613596




Registration number
NCT04613596
Ethics application status
Date submitted
28/10/2020
Date registered
3/11/2020
Date last updated
24/04/2024

Titles & IDs
Public title
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Scientific title
A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Secondary ID [1] 0 0
849-007
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced Non-Small Cell Lung Cancer 0 0
Metastatic Non-Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Adagrasib
Treatment: Drugs - Adagrasib
Treatment: Drugs - Adagrasib
Treatment: Drugs - Adagrasib
Treatment: Drugs - Pembrolizumab

Experimental: Phase 2 Cohort 1a: PD-L1 TPS <1% - Cohort 1a: Adagrasib twice daily (BID) in combination with pembrolizumab

Experimental: Phase 2 Cohort 1b: PD-L1 TPS <1% - Cohort 1b: Adagrasib BID monotherapy

Experimental: Phase 2 Cohort 2: PD-L1 TPS =1% - Cohort 2: Adagrasib BID in combination with pembrolizumab

Experimental: Phase 3 Cohort 3 Investigational Arm - Adagrasib BID in combination with pembrolizumab

Active Comparator: Phase 3 Cohort 4 Comparator Arm - Pembrolizumab


Treatment: Drugs: Adagrasib
Adagrasib 400 mg twice daily (BID) in combination with pembrolizumab (Cohort 1a)

Treatment: Drugs: Adagrasib
Adagrasib 600 mg BID monotherapy (Cohort 1b)

Treatment: Drugs: Adagrasib
adagrasib 400 mg BID in combination with pembrolizumab

Treatment: Drugs: Adagrasib
Adagrasib 400 mg BID + pembrolizumab 200 mg every Q3W

Treatment: Drugs: Pembrolizumab
Pembrolizumab 200 mg IV Q3W
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Phase 2: To evaluate the efficacy of Adagrasib monotherapy and in combination with pembrolizumab administered to patients having advanced/metastatic NSCLC.
Timepoint [1] 0 0
22 months
Primary outcome [2] 0 0
Phase 3: To compare efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumab
Timepoint [2] 0 0
36 months
Secondary outcome [1] 0 0
Phase 2: To characterize the safety and tolerability of study treatments in selected populations
Timepoint [1] 0 0
22 months
Secondary outcome [2] 0 0
Phase 2: Duration of Response
Timepoint [2] 0 0
22 months
Secondary outcome [3] 0 0
Phase 2: Progression Free Survival
Timepoint [3] 0 0
22 months
Secondary outcome [4] 0 0
Phase 2: To evaluate secondary efficacy endpoints using the study treatment in selected populations
Timepoint [4] 0 0
12 months
Secondary outcome [5] 0 0
Phase 2: To evaluate secondary efficacy endpoints using the study treatment in selected populations
Timepoint [5] 0 0
22 months
Secondary outcome [6] 0 0
Phase 2: To evaluate the pharmacokinetics (PK) of study treatments by measuring blood plasma MRTX849 and potential metabolite concentrations.
Timepoint [6] 0 0
22 months
Secondary outcome [7] 0 0
Phase 3: To evaluate the safety and tolerability in the study population
Timepoint [7] 0 0
36 months
Secondary outcome [8] 0 0
Phase 3: To evaluate the PK of adagrasib administered in the study population
Timepoint [8] 0 0
36 months
Secondary outcome [9] 0 0
Phase 3: To evaluate health-related quality of life (HRQOL) and lung cancer specific symptoms in the study population
Timepoint [9] 0 0
36 months
Secondary outcome [10] 0 0
Phase 3: Progression Free Survival per RECIST 1.1 by Investigator
Timepoint [10] 0 0
36 months
Secondary outcome [11] 0 0
Phase 3: Duration of Response (DOR) per RECIST 1.1 by Investigator and BICR
Timepoint [11] 0 0
36 months
Secondary outcome [12] 0 0
Phase 3: Objective Response Rate (ORR) per RECIST 1.1 by Investigator and BICR
Timepoint [12] 0 0
36 months

Eligibility
Key inclusion criteria
- Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with
KRAS G12C mutation and any PD-L1 TPS

- Phase 3: Histologically confirmed diagnosis of unresectable or metastatic squamous or
nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS >=50%

- Phase 3: Presence of evaluable or measurable disease per RECIST

- Phase 3: CNS Inclusion - Based on screening brain imaging, patients must have one of
the following:

1. No evidence of brain metastases

2. Untreated brain metastases not needing immediate local therapy

3. Previously treated brain metastases not needing immediate local therapy
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Phase 2 and Phase 3: Prior systemic treatment for locally advanced or metastatic NSCLC
including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting
KRAS G12C mutation (e.g., AMG 510).

- Phase 2: Active brain metastases

- Phase 3: Patients with known central nervous system (CNS) lesions must not have any of
the following:

1. Any untreated brain lesions > 1.0 cm in size

2. Any brainstem lesions

3. Ongoing use of systemic corticosteroids for control of symptoms of brain lesions
at a total daily dose of > 10 mg of prednisone (or equivalent) prior to
randomization.

4. Have poorly controlled (> 1/week) generalized or complex partial seizures, or
manifest neurologic progression due to brain lesions notwithstanding CNS-directed
therapy

- Phase 3: Radiation to the lung > 30 Gy within 6 months prior to the first dose of
study treatment

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2/Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/12/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/10/2029
Actual
Sample size
Target
806
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Research Site - Wollongong
Recruitment hospital [2] 0 0
Research Site - Woolloongabba
Recruitment hospital [3] 0 0
Research Site - Bedford Park
Recruitment hospital [4] 0 0
Research Site - Ballarat
Recruitment postcode(s) [1] 0 0
2500 - Wollongong
Recruitment postcode(s) [2] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [3] 0 0
5042 - Bedford Park
Recruitment postcode(s) [4] 0 0
3350 - Ballarat
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Louisiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Maryland
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Mississippi
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New York
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Oregon
Country [24] 0 0
United States of America
State/province [24] 0 0
South Dakota
Country [25] 0 0
United States of America
State/province [25] 0 0
Tennessee
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Virginia
Country [28] 0 0
Austria
State/province [28] 0 0
Carinthia
Country [29] 0 0
Austria
State/province [29] 0 0
Linz
Country [30] 0 0
Austria
State/province [30] 0 0
Vienna
Country [31] 0 0
Belgium
State/province [31] 0 0
Antwerpen
Country [32] 0 0
Belgium
State/province [32] 0 0
Vlaams Brabant
Country [33] 0 0
Belgium
State/province [33] 0 0
Hasselt
Country [34] 0 0
Canada
State/province [34] 0 0
Alberta
Country [35] 0 0
Canada
State/province [35] 0 0
British Columbia
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
Czechia
State/province [37] 0 0
Central Bohemian
Country [38] 0 0
Czechia
State/province [38] 0 0
Olomouc
Country [39] 0 0
Czechia
State/province [39] 0 0
Ostrava
Country [40] 0 0
Czechia
State/province [40] 0 0
Praha
Country [41] 0 0
Germany
State/province [41] 0 0
Baden-Wuerttemberg
Country [42] 0 0
Germany
State/province [42] 0 0
Bavaria
Country [43] 0 0
Germany
State/province [43] 0 0
Bayern
Country [44] 0 0
Germany
State/province [44] 0 0
Hessen
Country [45] 0 0
Germany
State/province [45] 0 0
Schleswig-Holstein
Country [46] 0 0
Germany
State/province [46] 0 0
Frankfurt
Country [47] 0 0
Germany
State/province [47] 0 0
Gießen
Country [48] 0 0
Germany
State/province [48] 0 0
Hemer
Country [49] 0 0
Germany
State/province [49] 0 0
Oldenburg
Country [50] 0 0
Hungary
State/province [50] 0 0
Budapest
Country [51] 0 0
Hungary
State/province [51] 0 0
Gyöngyös
Country [52] 0 0
Hungary
State/province [52] 0 0
Torokbalint
Country [53] 0 0
Ireland
State/province [53] 0 0
Dublin
Country [54] 0 0
Israel
State/province [54] 0 0
Afula
Country [55] 0 0
Israel
State/province [55] 0 0
Be'er Sheva
Country [56] 0 0
Israel
State/province [56] 0 0
Haifa
Country [57] 0 0
Israel
State/province [57] 0 0
Jerusalem
Country [58] 0 0
Israel
State/province [58] 0 0
Re?ovot
Country [59] 0 0
Israel
State/province [59] 0 0
Safed
Country [60] 0 0
Italy
State/province [60] 0 0
Forli-Cesena
Country [61] 0 0
Italy
State/province [61] 0 0
Bari
Country [62] 0 0
Italy
State/province [62] 0 0
Bologna
Country [63] 0 0
Italy
State/province [63] 0 0
Genova
Country [64] 0 0
Italy
State/province [64] 0 0
Milan
Country [65] 0 0
Italy
State/province [65] 0 0
Napoli
Country [66] 0 0
Italy
State/province [66] 0 0
Parma
Country [67] 0 0
Italy
State/province [67] 0 0
Roma
Country [68] 0 0
Italy
State/province [68] 0 0
Rome
Country [69] 0 0
Italy
State/province [69] 0 0
Varese
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Gyeonggi-do
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Busan
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Cheongju-si
Country [73] 0 0
Korea, Republic of
State/province [73] 0 0
Daegu
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Goyang-si
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Seoul
Country [76] 0 0
Netherlands
State/province [76] 0 0
Noord-Holland
Country [77] 0 0
Netherlands
State/province [77] 0 0
Zuid-Holland
Country [78] 0 0
Netherlands
State/province [78] 0 0
Harderwijk
Country [79] 0 0
Netherlands
State/province [79] 0 0
Utrecht
Country [80] 0 0
Poland
State/province [80] 0 0
Gdansk
Country [81] 0 0
Poland
State/province [81] 0 0
Lublin
Country [82] 0 0
Poland
State/province [82] 0 0
Otwock
Country [83] 0 0
Poland
State/province [83] 0 0
Skorzewo
Country [84] 0 0
Poland
State/province [84] 0 0
Torun
Country [85] 0 0
Portugal
State/province [85] 0 0
Lisbon
Country [86] 0 0
Portugal
State/province [86] 0 0
Porto
Country [87] 0 0
Spain
State/province [87] 0 0
Barcelona
Country [88] 0 0
Spain
State/province [88] 0 0
La Coruña
Country [89] 0 0
Spain
State/province [89] 0 0
Madrid
Country [90] 0 0
Spain
State/province [90] 0 0
Málaga
Country [91] 0 0
Spain
State/province [91] 0 0
Santiago De Compostela
Country [92] 0 0
Spain
State/province [92] 0 0
Sevilla
Country [93] 0 0
Spain
State/province [93] 0 0
Valencia
Country [94] 0 0
Taiwan
State/province [94] 0 0
Tainan City
Country [95] 0 0
United Kingdom
State/province [95] 0 0
England
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Leicester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Mirati Therapeutics Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy
and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS
G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment.

The Phase 3 portion of the study compares the efficacy of adagrasib in combination with
pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or
metastatic nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS >=50% and who are
candidates for first line treatment.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04613596
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Barbara Wamil, MD
Address 0 0
Mirati Therapeutics Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Mirati Therapeutics Study Locator Services
Address 0 0
Country 0 0
Phone 0 0
18448935530
Fax 0 0
Email 0 0
miratistudylocator@careboxhealth.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04613596